Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer: a systematic review and meta-analysis

World Journal of Surgical Oncology

Caizhao Lin¹  Xile Zhou¹ 

[1] Department of Colorectal Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, Zhejiang, P.R. China

关键词: Meta-analysis;    Polymorphism;    Angiotensin-converting enzyme;    Survivin;    Colorectal cancer;   

Others  :  1146276
DOI  :  10.1186/s12957-015-0461-5

 received in 2014-09-23, accepted in 2015-01-10,  发布年份 2015

【 摘 要 】

Background

Colorectal cancer (CRC) is the most common cause of cancer death worldwide. Numerous studies have identified the roles of survivin −31 G/C and angiotensin-converting enzyme insertion/deletion (ACE I/D) polymorphisms in CRC risk; however, the results remain inconclusive. This study was to investigate associations between these two polymorphisms and CRC susceptibility.

Methods

A comprehensive literature search was conducted to collect relevant case–control studies published between 2000 and 2014. The extracted data were statistically analyzed, and the odds ratios (ORs) with 95% confidence intervals (CIs) were employed to estimate the strength of association.

Results

A total of 11 studies were included in the meta-analysis. For survivin G/C polymorphism, six articles reported 1,840 cases and 1,804 controls. Overall, we found the frequency of C allele is higher in CRC cases than that in the healthy controls (57.2% vs. 48.0%), and C allele significantly increased the risk of CRC compared to G allele in allele model (OR = 1.46, 95% CI = 1.33–1.60, P < 0.00001). This association was also found in other genetic models (P < 0.00001). Stratified analysis by ethnicity showed significant association in each genetic model among the Asian population. For ACE I/D polymorphism, five studies included 758 cases and 6,755 controls. No significant association was found in any genetic models.

Conclusions

Our results showed that survivin −31 G/C polymorphism might contribute to risk of CRC, especially in the Asian populations. However, the ACE I/D polymorphism is not a genetic factor concerning the risk for CRC. More studies with larger sample sizes are required in the future.

【 授权许可】

   
2015 Zhou and Lin; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Wasserman M, Baxter N, Rosen B, Burnstein M, Halverson A. Systematic review of internet patient information on colorectal cancer surgery. Dis Colon Rectum. 2014; 57(1):64-9.
• [2]Mäkinen MJ. Serrated polyps and colorectal cancer risk. Colorectal Cancer. 2014; 3(1):77-91.
• [3]Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17.
• [4]Derks S, van Engeland M. Epigenetic disturbances in colorectal cancer. Epigenetic Therapy of Cancer. Springer; 2014. p. 283–98.
• [5]Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6:479-507.
• [6]Srinivasula SM, Ashwell JD. IAPs: what’s in a name? Mol Cell. 2008; 30(2):123-35.
• [7]Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008; 8(1):61-70.
• [8]Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997; 3(8):917-21.
• [9]Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos F-I, Marousi S et al.. The survivin-31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol. 2011; 34(4):381-91.
• [10]Krege JH, Kim H-S, Moyer JS, Jennette JC, Peng L, Hiller SK et al.. Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension. 1997; 29(1):150-7.
• [11]Feng Y, Wan H, Liu J, Zhang R, Ma Q, Han B et al.. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep. 2010; 23(4):941-8.
• [12]Zhang Y, He J, Deng Y, Zhang J, Li X, Xiang Z et al.. The insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme gene and cancer risk: a meta-analysis. BMC Med Genet. 2011; 12(1):159. BioMed Central Full Text
• [13]Mc Menamin ÚC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012; 23(2):221-30.
• [14]Makar GA, Holmes JH, Yang Y-X. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst. 2014; 106(2):djt374.
• [15]Sameer A, Nissar S, Bashir S, Bashir A, Siddiqi M. ACE polymorphism in colorectal cancer patients of Kashmiri population—a short report. Open Colorectal Canc J. 2011; 4:1-5.
• [16]Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A et al.. Survivin −31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 2009; 24(2):145-50.
• [17]Huang J, Wang J, Wang L, Liu H, Wei Y, Huang M et al.. Association between Survivin Promoter -31C/G Polymorphism and Genetic Susceptibility to Sporadic Colorectal Cancer. J SUN Yat-sen Univ (Med Sci). 2010; 31(1):59-63. (in chinese)
• [18]Duan F. The Study on the Relationship between Survivin promoter SNP and the Colorectal Cancer. Master's thesis. Lu Zhou medical college, 2012. (in chinese)
• [19]Liu Y. The Association of Survivin Polymorphism with the Risk of Colorectal Cancer. Master's thesis. Hebei medical college, 2012. (in chinese)
• [20]Li XB, Li SN, Yang ZH, Cao L, Duan FL, Sun XW. Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. DNA Cell Biol. 2013; 32(5):236-42.
• [21]Nikiteas N, Tsigris C, Chatzitheofylaktou A, Yannopoulos A. No association with risk for colorectal cancer of the insertion/deletion polymorphism which affects levels of angiotensin-converting enzyme. In Vivo. 2007; 21(6):1065-68.
• [22]Rocken C, Neumann K, Carl-McGrath S, Lage H, Ebert MP, Dierkes J et al.. The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia. 2007; 9(9):716-22.
• [23]Van der Knaap R, Siemes C, Coebergh JW, Van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer. 2008; 112(4):748-57.
• [24]Toma M, Cimponeriu D, Apostol P, Stavarachi M, Cojocaru M, Belusica L et al.. Lack of association between ACE ID polymorphism and colorectal cancer in Romanian patients. Chirurgia (Bucharest, Romania: 1990). 2008; 104(5):553-56.
• [25]Liu SY, Sima X, Wang CH, Gao M. The association between ACE polymorphism and risk of colorectal cancer in a Chinese population. Clin Biochem. 2011; 44(14):1223-26.
• [26]Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F et al.. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res. 2003; 63(15):4507-15.
• [27]Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T et al.. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001; 91(11):2026-32.
• [28]Fan L-F, Dong W-G, Jiang C-Q, Qian Q, Yu Q-F. Role of hypoxia-inducible factor-1α and survivin in colorectal carcinoma progression. Int J Color Dis. 2008; 23(11):1057-64.
• [29]Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH et al.. Polymorphisms in the < i > survivin  gene and the risk of lung cancer. Lung Cancer. 2008; 60(1):31-9.
• [30]Qin Q, Zhang C, Zhu H, Yang X, Xu L, Liu J et al.. Association between survivin-31G > C polymorphism and cancer risk: meta-analysis of 29 studies. J Cancer Res Clin Oncol. 2014; 140(2):179-88.
• [31]Skoufias DA, Mollinari C, Lacroix FB, Margolis RL. Human survivin is a kinetochore-associated passenger protein. J Cell Biol. 2000; 151(7):1575-82.
• [32]Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K et al.. An IAP-IAP complex inhibits apoptosis. J Biol Chem. 2004; 279(33):34087-90.
• [33]Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y et al.. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol. 2012; 105(6):520-8.
• [34]Choi J, Chang H. The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. Anticancer Res. 2012; 32(2):559-64.
• [35]Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003; 362(9379):205-9.
• [36]Ma Y, Wang HS. Correlations of Bcl-2 and survivin gene protein expressions in colorectal cancer. Appl Mech Mater. 2013; 423:362-5.
• [37]Goossens-Beumer I, Zeestraten E, Benard A, Christen T, Reimers M, Keijzer R et al.. Clinical prognostic value of combined analysis of Aldh1, survivin, and EpCAM expression in colorectal cancer. Br J Cancer. 2014; 110(12):2935-44.
• [38]Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014; 15(2):2494-516.
• [39]Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen D-T et al.. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011; 10(3):188-93.
• [40]Krieg A, Werner TA, Verde PE, Stoecklein NH, Knoefel WT. Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis. PLoS One. 2013; 8(6):e65338.
• [41]Guang C, Phillips RD, Jiang B, Milani F. Three key proteases–angiotensin-I-converting enzyme (ACE), ACE2 and renin—within and beyond the renin-angiotensin system. Arch Cardiovasc Dis. 2012; 105(6):373-85.
• [42]Yates CJ, Masuyer G, Schwager SL, Akif M, Sturrock ED, Acharya KR. Molecular and thermodynamic mechanisms of the chloride-dependent human angiotensin-I-converting enzyme (ACE). J Biol Chem. 2014; 289(3):1798-814.
• [43]Xie Y, You C, Chen J. An updated meta-analysis on association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and cancer risk. Tumor Biol. 2014; 35(7):6567-79.
• [44]Yuan F, Zhang L-S, Li H-Y, Liao M, Lv M, Zhang C. Influence of angiotensin I-converting enzyme gene polymorphism on hepatocellular carcinoma risk in China. DNA Cell Biol. 2013; 32(5):268-73.
• [45]Liu J-F, Xie H-J, Cheng T-M. Lack of any association between insertion/deletion (I/D) polymorphisms in the angiotensin-converting enzyme gene and digestive system cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2013; 14(12):7271-5.